Sepsis kills 11 million people yearly, with each hour of delayed treatment raising mortality risk by nearly 8%. Yet today’s gold standard diagnostic—blood culture—can take up to 48 hours, while sepsis can cause death in just 12. Inadequate antibiotics can reduce survival 5-fold, and misuse fuels Antimicrobial Resistance (AMR), projected to kill 10 million annually by 2050.
Zyn-Sepsis is a rapid, all-in-one in vitro diagnostic test for detecting and identifying bacterial pathogens in blood. It senses bacteria-specific gas biomarkers (VOCs) during their growth phase and applies machine learning to recognize unique VOC “fingerprints.” The result: fast, accurate identification in about 4 hours—with high sensitivity and specificity.
13.09.2023
Zynnon's Clinical Study Yields Promising Results (startupticker.ch)
03.08.2022
"If not you, then who?" — Interview with Maria Luisa Fuchs of Startup@HSG at the University of St. Gallen (venturelab.swiss)
27.06.2022
Zynnon raises CHF800,000 to lower the risk of respiratory infection transmission (startupticker.ch)
26.09.2024
12.09.2024
15.07.2024
Positive lab test results opening new microbiology markets
20.12.2023
No Jobs
No videos and documents
No Awards
Website:
zynnon.com
Headquarter:
Schindellegi
Foundation Date:
November 2019
Technology:
Sectors: